JP2017507117A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507117A5
JP2017507117A5 JP2016546462A JP2016546462A JP2017507117A5 JP 2017507117 A5 JP2017507117 A5 JP 2017507117A5 JP 2016546462 A JP2016546462 A JP 2016546462A JP 2016546462 A JP2016546462 A JP 2016546462A JP 2017507117 A5 JP2017507117 A5 JP 2017507117A5
Authority
JP
Japan
Prior art keywords
hpv
antigen
antibody
composition
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016546462A
Other languages
English (en)
Japanese (ja)
Other versions
JP7037884B2 (ja
JP2017507117A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011236 external-priority patent/WO2015106281A1/en
Publication of JP2017507117A publication Critical patent/JP2017507117A/ja
Publication of JP2017507117A5 publication Critical patent/JP2017507117A5/ja
Priority to JP2021197509A priority Critical patent/JP7536737B2/ja
Application granted granted Critical
Publication of JP7037884B2 publication Critical patent/JP7037884B2/ja
Priority to JP2024086175A priority patent/JP2024112966A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016546462A 2014-01-13 2015-01-13 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン Expired - Fee Related JP7037884B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021197509A JP7536737B2 (ja) 2014-01-13 2021-12-06 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2024086175A JP2024112966A (ja) 2014-01-13 2024-05-28 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461926821P 2014-01-13 2014-01-13
US61/926,821 2014-01-13
US201462002718P 2014-05-23 2014-05-23
US62/002,718 2014-05-23
PCT/US2015/011236 WO2015106281A1 (en) 2014-01-13 2015-01-13 Novel vaccines against hpv and hpv-related diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019207238A Division JP2020036612A (ja) 2014-01-13 2019-11-15 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2021197509A Division JP7536737B2 (ja) 2014-01-13 2021-12-06 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン

Publications (3)

Publication Number Publication Date
JP2017507117A JP2017507117A (ja) 2017-03-16
JP2017507117A5 true JP2017507117A5 (enExample) 2018-02-22
JP7037884B2 JP7037884B2 (ja) 2022-03-17

Family

ID=53524425

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016546462A Expired - Fee Related JP7037884B2 (ja) 2014-01-13 2015-01-13 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2019207238A Pending JP2020036612A (ja) 2014-01-13 2019-11-15 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2021197509A Active JP7536737B2 (ja) 2014-01-13 2021-12-06 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2024086175A Pending JP2024112966A (ja) 2014-01-13 2024-05-28 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019207238A Pending JP2020036612A (ja) 2014-01-13 2019-11-15 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2021197509A Active JP7536737B2 (ja) 2014-01-13 2021-12-06 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP2024086175A Pending JP2024112966A (ja) 2014-01-13 2024-05-28 Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン

Country Status (8)

Country Link
US (5) US10286058B2 (enExample)
EP (2) EP3094652B1 (enExample)
JP (4) JP7037884B2 (enExample)
CN (2) CN106103483A (enExample)
AU (1) AU2015204503B2 (enExample)
CA (1) CA2936833A1 (enExample)
IL (1) IL246759A0 (enExample)
WO (1) WO2015106281A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105884903B (zh) * 2009-03-10 2019-12-06 贝勒研究院 靶向抗原呈递细胞的疫苗
CN103415534A (zh) * 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
CN106103483A (zh) * 2014-01-13 2016-11-09 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
WO2017015504A1 (en) * 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
BR112018067550A2 (pt) * 2016-02-27 2019-10-01 Hpvvax, Llc. métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica
CA3036509C (en) 2016-09-19 2022-10-25 I-Mab Anti-gm-csf antibodies and uses thereof
ES2883720T3 (es) 2016-11-07 2021-12-09 Us Health Desarrollo de epítopos agonistas del virus del papiloma humano
CN109021097A (zh) * 2017-06-08 2018-12-18 艾托金生物医药（苏州）有限公司 一种识别hpv18和/或hpv45的单克隆抗体及其应用
CN109384848A (zh) * 2017-08-10 2019-02-26 深圳市雅臣智能生物工程有限公司 抗人乳头瘤病毒和抗cd人源化的双靶向抗体及其组合物、制备方法和应用
CN112088015A (zh) 2018-03-06 2020-12-15 普莱西根股份有限公司 人乳头瘤病毒疫苗及其用途
JP7640466B2 (ja) * 2019-03-27 2025-03-05 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル Ｃｄ４０活性化特性を有する組換えタンパク質
CN110054686A (zh) * 2019-04-17 2019-07-26 深圳市雅臣智能生物工程有限公司 抗广谱HPV-L1、E6/E7-IgY及其小分子抗体以及应用
CN111620955B (zh) * 2020-07-01 2022-11-08 北京康爱瑞浩细胞技术有限公司 一种多靶位复合抗原及其应用
WO2022136508A1 (en) * 2020-12-23 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
KR20230135620A (ko) * 2021-01-29 2023-09-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 클라미디아 트라코마티스 항원 폴리펩타이드 및 백신목적을 위한 이의 용도
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
CN116621971B (zh) * 2022-12-16 2025-03-25 生物岛实验室 Hpv18亚型的纳米抗体及其应用
WO2024145863A1 (en) * 2023-01-05 2024-07-11 Virogin Biotech (Shanghai) Ltd. A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
CN119215159A (zh) * 2024-09-24 2024-12-31 深圳市格茵莱生物科技有限公司 树突状细胞多抗原负载免疫治疗方法

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403608A (en) 1940-12-19 1946-07-09 Socony Vacuum Oil Co Inc Method of coking oils
US2609508A (en) 1943-04-24 1952-09-02 Bell Telephone Labor Inc Wave generating circuits
US2489708A (en) 1945-01-12 1949-11-29 United Metal Box Co Inc Shelf support combination and cabinet
US2501008A (en) 1948-08-23 1950-03-21 John G Schramm Safety knob
CH482813A (de) 1967-06-16 1969-12-15 Ciba Geigy Flockulationsbeständige Pigmentpräparate und Verfahren zu deren Herstellung
US3613808A (en) 1968-12-18 1971-10-19 Fmc Corp Article-sorting apparatus with transfer-error-reducing arrangement
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
DE69311538D1 (de) 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ATE153380T1 (de) 1993-01-16 1997-06-15 Manfred Schawaller Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
IL110852A (en) * 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6040137A (en) 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1033406A4 (en) 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
US6573245B1 (en) 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
WO2000000156A2 (en) 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001026608A2 (en) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
GB9926084D0 (en) 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DK1282646T3 (da) 2000-05-08 2012-05-14 Celldex Res Corp Humane monoklonale antistoffer mod dendritiske celler
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
AU2001296547A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗ｃｄ４０モノクローナル抗体
EP2009027B1 (en) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
FR2837104B1 (fr) 2002-03-14 2004-08-06 Dev Des Antigenes Combinatoire Utilisation de melange de lipopeptides pour la fabrication de vaccins
EP1551453A4 (en) 2002-06-17 2007-04-25 Us Gov Health & Human Serv SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN100381463C (zh) 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
JP2006506072A (ja) 2002-11-12 2006-02-23 デイッセロース，アルバート，ビー アデノウイルスベクターワクチン
JP2004192125A (ja) 2002-12-09 2004-07-08 Mitsue-Links Co Ltd プロジェクトマネジメントシステム及びそれに用いられるデータ構造、並びに、プロジェクトマネジメント方法
GB0228796D0 (en) 2002-12-11 2003-01-15 Adjuvantix Ltd Valency
CA2514270A1 (en) 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
EP2862878B1 (en) 2003-02-25 2022-11-02 Nykode Therapeutics ASA Modified antibody
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ES2397631T3 (es) 2003-12-25 2013-03-08 Kyowa Hakko Kirin Co., Ltd. Mutante antagonista de anticuerpos ANTI-CD40
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
JP2007026135A (ja) 2005-07-19 2007-02-01 Shimizu Corp プログラムマネジメントチャート作成支援システム
CA2620667A1 (en) 2005-08-30 2007-04-12 Board Of Regents Of The University Of Nebraska Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity
CA2623329A1 (en) 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
WO2007051169A2 (en) 2005-10-28 2007-05-03 Centocor, Inc. Use of b cell expansion agents in generating antibodies
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
JP5345053B2 (ja) * 2006-04-19 2013-11-20 浦項工科大學校 産學協力團 子宮頸癌の予防及び治療のためのヒトパピローマウイルスポリペプチドと免疫増強剤を含む組成物
US7993648B2 (en) 2006-05-03 2011-08-09 The Regents of the Universitry of Colorado Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
CA2989780C (en) 2006-09-14 2022-08-09 Veveo, Inc. Methods and systems for dynamically rearranging search results into hierarchically organized concept clusters
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
US20080241139A1 (en) 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
NZ578696A (en) 2007-02-02 2012-01-12 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
US7786267B2 (en) 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2522718B1 (en) 2007-02-23 2014-03-26 Baylor Research Institute Therapeutic applications of activation of human antigen-presenting cells through dectin-1
BRPI0807613A2 (pt) 2007-02-23 2014-06-10 Baylor Res Inst Ativação de antígeno humano presente em células através de clec-6
TWI556826B (zh) 2007-02-23 2016-11-11 貝勒研究協會 經由樹突狀細胞凝集素樣氧化型低密度脂蛋白受體－１（ｌｏｘ－１）之人類抗原呈現細胞活化
CN108948177B (zh) 2007-05-11 2022-04-22 阿尔托生物科学有限公司 融合分子与il-15变异体
AP2010005284A0 (en) 2007-11-02 2010-06-30 Univ Johns Hopkins Multitype HPV peptide compositions and methods fortreatment or prevention of human papillomavirus i nfection
JP5233505B2 (ja) 2008-03-17 2013-07-10 株式会社リコー 共同作業支援装置、共同作業支援システム、共同作業支援方法、プログラムおよび記録媒体
RU2539765C2 (ru) 2008-07-16 2015-01-27 Бейлор Рисёч Инститьют ВИЧ ВАКЦИНА, ОСНОВАННАЯ НА НАПРАВЛЕННОСТИ МАКСИМИЗИРОВАННЫХ Gag И Nef НА ДЕНДРИТНЫЕ КЛЕТКИ
CA2735421A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
CN105884903B (zh) 2009-03-10 2019-12-06 贝勒研究院 靶向抗原呈递细胞的疫苗
ES2584956T3 (es) 2009-03-10 2016-09-30 Baylor Research Institute Anticuerpos anti-CD40 y usos de los mismos
EP2424990A4 (en) 2009-04-28 2013-05-15 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR REINFORCING ANTIGEN-SPECIFIC IMMUNE REACTIONS
CN102574908B (zh) 2009-08-27 2018-08-03 诺沃—诺迪斯克有限公司 组织因子向活化的血小板的靶向
AU2010291939B2 (en) 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells
WO2011070124A2 (en) 2009-12-10 2011-06-16 Fruitful Innovations B.V. Improved catalytic process for reacting carbon dioxide with hydrogen
GB201003293D0 (en) * 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
MX2012012833A (es) 2010-05-07 2012-11-30 Baylor Res Inst Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
WO2011158019A1 (en) * 2010-06-16 2011-12-22 Adjuvantix Limited Polypeptide vaccine
RU2013110889A (ru) 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
JP5022520B2 (ja) 2010-09-01 2012-09-12 有限会社栄ライト工業所 計画作成支援プログラム及び計画作成支援システム
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CA2830987A1 (en) 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
AR085573A1 (es) * 2011-03-25 2013-10-09 Baylor Res Inst Composiciones y metodos de inmunizacion contra el virus de la hepatitis c
AR088428A1 (es) 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
CA2858963C (en) 2011-12-21 2023-05-23 Vaccibody As Vaccines against hpv
CN106103483A (zh) * 2014-01-13 2016-11-09 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
JP2017507117A5 (enExample)
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
Jagu et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines
Dochez et al. HPV vaccines to prevent cervical cancer and genital warts: an update
Khallouf et al. Therapeutic vaccine strategies against human papillomavirus
Huber et al. RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates
Tran et al. Control of HPV infection and related cancer through vaccination
Kumar et al. HPV vaccine: Current status and future directions
CN107163107B (zh) 用于治疗或预防人乳头瘤病毒感染的多型hpv肽的组合物和方法
Lee et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects
JP2013532971A5 (enExample)
Jagu et al. Optimization of multimeric human papillomavirus L2 vaccines
Tyler et al. Second-generation prophylactic HPV vaccines: successes and challenges
Komatsu et al. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells
Kawana et al. Human papillomavirus vaccines: current issues & future
JP2015529678A5 (enExample)
Olczak et al. Progress in L2-based prophylactic vaccine development for protection against diverse human papillomavirus genotypes and associated diseases
EA201071366A1 (ru) Комбинированная вакцина против кори и вируса папилломы человека
HK1258860A1 (zh) 含有重组李斯特氏菌株的免疫治疗制剂的制作方法
JP2019525735A (ja) Ｈｐｖ ｌ２ペプチドの免疫原性の改善
Jiang et al. Progress and prospects for L2-based human papillomavirus vaccines
Venuti et al. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer
Kalnin et al. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes
Ribeiro-Müller et al. Prophylactic papillomavirus vaccines
Mishra et al. HPV vaccine: One, two, or three doses for cervical cancer prevention?